Clinical trial
Can we Rely on HLA to Predict Resistance to Biological Therapy in IBD Patients
NCT05040854 is registered in ClinicalTrials.gov with Centro Hospitalar Tondela-Viseu as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Can we Rely on HLA to Predict Resistance to Biological Therapy in IBD Patients
- Lead sponsor
- Centro Hospitalar Tondela-Viseu
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- July 1, 2021
- Completion date
- July 1, 2024
- Enrollment
- 600 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.